Kotmayer Lili, Kozyra Emilia J, Kang Guolian, Strahm Brigitte, Yoshimi Ayami, Sahoo Sushree S, Pastor Victor B, Attardi Enrico, Voss Rebecca, Vinci Luca, Kaiser Max, Dworzak Michael N, De Moerloose Barbara, Sukova Martina, Starý Jan, Hasle Henrik, Jahnukainen Kirsi, Polychronopoulou Sophia, Kállay Krisztián, Smith Owen P, Malone Andrea, Barzilai Birenboim Shlomit, Masetti Riccardo, Buechner Jochen, Ussowicz Marek, Kjöllerström Paula, Bodova Ivana, Kavcic Marko, Català Albert, Turkiewicz Dominik, Schmugge Markus, de Haas Valerie, Okhomina Victoria I, Sotomayor Cristian, Catalán Paula, Wehr Claudia, Salzer Ulrich, Germing Ulrich, Gattermann Norbert, Bödör Csaba, Gray Nathan, Lewis Sara, Shimamura Akiko, Giorgetti Alessandra, Erlacher Miriam, Niemeyer Charlotte M, Wlodarski Marcin W
Department of Hematology, St. Jude Children's Research Hospital, Memphis, USA.
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Blood Cancer J. 2025 Jul 15;15(1):121. doi: 10.1038/s41408-025-01309-6.
GATA2 deficiency is an autosomal dominant transcriptopathy disorder with high risk for myelodysplastic syndrome (MDS). To elucidate genotype-phenotype associations and identify new genetic risk factors for MDS, we analyzed 218 individuals with germline heterozygous GATA2 variants. We observed striking age-dependent incidence patterns in GATA2-related MDS (GATA2-MDS), with MDS being absent in infants, rare before age 6 years, and steeply increasing in older children. Among 108 distinct GATA2 variants (67 novel), null mutations conferred a 1.7-fold increased risk for MDS, had earlier MDS onset compared to other variants (12.2 vs. 14.6 years, p = 0.009) and were associated with lymphedema and deafness. In contrast, intron 4 variants exhibited reduced penetrance and lower risk for MDS development. Analysis of the somatic landscape revealed unique patterns of clonal hematopoiesis. SETBP1 mutations occurred exclusively in patients with monosomy 7 and their frequency decreased with age. Conversely, the frequency of STAG2 mutations and trisomy 8 increased with age and appeared protective against early development of advanced MDS. Overall, the majority (73.9%) of mutation-positive cases harbored monosomy 7, suggesting it serves as a major driver in malignant progression. Our findings provide evidence for age-appropriate surveillance, and a foundation for genotype-driven risk stratification in GATA2 deficiency.
GATA2缺陷是一种常染色体显性转录病性疾病,患骨髓增生异常综合征(MDS)风险高。为阐明基因型与表型的关联并确定MDS的新遗传风险因素,我们分析了218名携带种系杂合GATA2变异的个体。我们观察到GATA2相关MDS(GATA2-MDS)存在显著的年龄依赖性发病模式,婴儿期无MDS,6岁前罕见,而大龄儿童中则急剧增加。在108种不同的GATA2变异(67种为新变异)中,无效突变使MDS风险增加1.7倍,与其他变异相比MDS发病更早(12.2岁对14.6岁,p = 0.009),且与淋巴水肿和耳聋相关。相比之下,内含子4变异的外显率降低且MDS发生风险较低。对体细胞格局的分析揭示了克隆性造血的独特模式。SETBP1突变仅发生在7号染色体单体患者中,其频率随年龄降低。相反,STAG2突变和8号染色体三体的频率随年龄增加,且似乎对晚期MDS的早期发展有保护作用。总体而言,大多数(73.9%)突变阳性病例存在7号染色体单体,表明其是恶性进展的主要驱动因素。我们的研究结果为进行适合年龄的监测提供了证据,并为GATA2缺陷中基于基因型的风险分层奠定了基础。